Evolve starts commercial resveratrol production

Reinach, Switzerland, 28 May 2014 – Evolva Holding SA (SIX: EVE) today announces the start of commercial production of its resveratrol ingredient. Evolva has succeeded in optimising and scaling the fermentation process, resulting in competitive production costs that allow a commercial launch. Evolva’s resveratrol is high-purity (>98% pure trans-Resveratrol), with a controlled and reliable supply chain, produced from natural and sustainable feedstocks. It is the only resveratrol product made by brewing.

Evolva has appointed a contract manufacturer in North America to produce commercial batches of resveratrol and expects to receive first deliveries in Q3 2014. Work on further reducing production costs will continue post-launch. Discussions with a global network of distributors are ongoing to accelerate sales post-launch.

Evolva has commenced pre-launch commercial activities and will attend the Institute of Food Technologist (IFT) Annual Meeting and Food Expo on 22-24 June (New Orleans, USA). Amongst other launch activities planned for resveratrol in the second half of 2014, Evolva will have a booth at the SupplySide West 2014 Expo (Las Vegas, USA) between 6-10 October 2014. At this Expo, executives from around the world gather to discuss the latest trends in the areas of animal nutrition, personal care, food, beverage and dietary supplements.

- ends -

About Evolva

Evolva is a pioneer and global leader in sustainable, fermentation-based approaches to ingredients for health, wellness and nutrition. Evolva’s products include stevia, vanilla, saffron and resveratrol. As well as developing its own proprietary ingredients, Evolva also deploys its technology for partners, providing them with a competitive edge and sharing in the returns they make. For more information see www.evolva.com.

About resveratrol

Resveratrol is a compound produced in grapes and other plants. It occurs in red wine, albeit at low concentrations. Scientific and clinical research indicates that resveratrol may have benefits against several age related health conditions, in particular those associated with diabetes, inflammation and cardiovascular health.
Most resveratrol products on the market today are low-purity Chinese extracts obtained from the roots of the Japanese knotweed, an invasive weed. Other natural sources include the skin of grapes and berries such as lingonberries but commercially available products tend to be low purity and expensive. There is also a synthetic version of resveratrol.

Evolva’s product is high-purity (>98%), with a controlled and reliable supply chain, produced via yeast fermentation from natural and sustainable feedstocks. It is the only resveratrol product made by brewing. It has Self-Affirmed GRAS (“Generally Recognised As Safe”) status in the United States and Novel Foods authorisation in the European Union for use in Dietary Supplements. A ruling in 2013 by the Japanese Ministry of Health, Labor and Welfare is expected to facilitate the approval process for the product in Japan.

Today, by far the largest use of resveratrol is in dietary supplements but there is considerable room for expansion as the market is still in its infancy. Over time Evolva believes resveratrol could also be used more widely in food and beverage products, personal care and animal health and nutrition.

Contact Details

Neil Goldsmith, CEO  
neilg@evolva.com  
+ 41 61 485 2005

Jakob Dynnes Hansen, CFO  
jakobdh@evolva.com  
+ 41 61 485 2034

Paul Verbraeken, IR  
paulv@evolva.com  
+ 41 61 485 2035

Commercial enquiries  
resveratrol@evolva.com

This press release contains specific forward-looking statements, e.g. statements including terms like believe, assume, expect or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of the company and those explicitly or implicitly presumed in these statements. Against the background of these uncertainties readers should not place undue reliance on forward-looking statements. The company assumes no responsibility to update forward-looking statements or to adapt them to future events or developments.